Literature DB >> 10812286

Antinociceptive, subjective and behavioral effects of smoked marijuana in humans.

M K Greenwald1, M L Stitzer.   

Abstract

The purpose of this study was to determine whether marijuana produced dose-dependent antinociception in humans and, if so, whether endogenous opiates modulate this effect. A total of five male regular marijuana users participated in three test sessions during which they smoked cigarettes containing 0% (placebo) and 3. 55% Delta(9)-tetrahydrocannabinol (Delta(9)-THC) (active). Each of four controlled smoking bouts per session, spaced at 40-min intervals, consisted of nine puffs from active and placebo cigarettes (three cigarettes, three puffs per cigarette, one puff per min). During successive bouts, participants smoked 0, 3, 6 and 9 (0, 3, 9 and 18 cumulative) puffs from active marijuana cigarettes, with the remainder of puffs from placebo cigarettes. Test sessions were identical, except for naltrexone 0, 50 or 200 mg p.o. (randomized, double-blind) administration 1 h before the first smoking bout on the different days. Before smoking, between smoking bouts and postsmoking, participants completed an assessment battery that included antinociceptive (finger withdrawal from radiant heat stimulation), biological, subjective, observer-rated signs and performance measures. Marijuana produced significant dose-dependent antinociception (increased finger withdrawal latency) and biobehavioral effects. Naltrexone did not significantly influence marijuana dose-effect curves, suggesting no role of endogenous opiates in marijuana-induced antinociception under these conditions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10812286     DOI: 10.1016/s0376-8716(99)00128-3

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  48 in total

Review 1.  State of the art treatments for cannabis dependence.

Authors:  Itai Danovitch; David A Gorelick
Journal:  Psychiatr Clin North Am       Date:  2012-04-10

Review 2.  [Palliative pain therapy, cannabinoids].

Authors:  L Radbruch; F Elsner
Journal:  Internist (Berl)       Date:  2005-10       Impact factor: 0.743

3.  A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain.

Authors:  Barth Wilsey; Thomas Marcotte; Alexander Tsodikov; Jeanna Millman; Heather Bentley; Ben Gouaux; Scott Fishman
Journal:  J Pain       Date:  2008-04-10       Impact factor: 5.820

Review 4.  The Impact of Perioperative Cannabis Use: A Narrative Scoping Review.

Authors:  Karim S Ladha; Varuna Manoo; Ali-Faizan Virji; John G Hanlon; Alexander Mclaren-Blades; Akash Goel; Duminda N Wijeysundera; Lakshmi P Kotra; Carlos Ibarra; Marina Englesakis; Hance Clarke
Journal:  Cannabis Cannabinoid Res       Date:  2019-12-06

5.  Cannabidiol-Δ9-tetrahydrocannabinol interactions on acute pain and locomotor activity.

Authors:  Stevie C Britch; Jenny L Wiley; Zhihao Yu; Brian H Clowers; Rebecca M Craft
Journal:  Drug Alcohol Depend       Date:  2017-04-15       Impact factor: 4.492

6.  Low-dose vaporized cannabis significantly improves neuropathic pain.

Authors:  Barth Wilsey; Thomas Marcotte; Reena Deutsch; Ben Gouaux; Staci Sakai; Haylee Donaghe
Journal:  J Pain       Date:  2012-12-11       Impact factor: 5.820

7.  Sex-dependent effects of cannabis-induced analgesia.

Authors:  Ziva D Cooper; Margaret Haney
Journal:  Drug Alcohol Depend       Date:  2016-08-05       Impact factor: 4.492

Review 8.  Quantifying reinforcement value and demand for psychoactive substances in humans.

Authors:  Adrienne J Heinz; Todd C Lilje; Jon D Kassel; Harriet de Wit
Journal:  Curr Drug Abuse Rev       Date:  2012-12

9.  The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Authors:  Zuzana Justinova; Gianluigi Tanda; Patrik Munzar; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

Review 10.  Clinical models of decision making in addiction.

Authors:  Mikhail N Koffarnus; Brent A Kaplan
Journal:  Pharmacol Biochem Behav       Date:  2017-08-26       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.